| Document |
Document Title |
|
WO/2024/075794A1 |
Provided is a novel anti-influenza virus agent which inhibits the growth and infection mechanisms of influenza virus and thus has a target other than specific viral proteins and which does not cause the emergence of drug-resistant viruse...
|
|
WO/2024/050516A3 |
Provided herein are compounds, pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds or pharmaceutically acceptable salts thereof, kits containing these compounds or pharmaceutically acceptable salts t...
|
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
|
WO/2024/076677A2 |
Disclosed herein are imidazolyl-alkoxyquinolin-2-amines, pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interfero...
|
|
WO/2024/077262A2 |
Disclosed are compositions and methods for reducing expression of ELAVL2. It has been determined that GGGGCC (G4C2) repeat expansion in the first intron of C9ORF72 is the most commonly known genetic cause of amyotrophic lateral sclerosis...
|
|
WO/2024/074127A1 |
Provided compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer the...
|
|
WO/2024/030766A9 |
Provided herein are compositions and formulations for alleviating problems associated with unregulated intraocular pressure (IOP) in an eye comprising the administration of Trabodenoson. Administration of Trabodenoson results in reversin...
|
|
WO/2024/030535A3 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally re...
|
|
WO/2024/077036A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, and compounds of Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (...
|
|
WO/2024/077087A2 |
The present technology relates generally to compounds for inhibiting M24B aminopeptidases to selectively activating the CARDS inflammasome, an innate immune signaling platform that triggers pyroptotic cell death.
|
|
WO/2024/074483A1 |
The present invention relates to compositions for use in the treatment, amelioration, and or prevention of myotonic dystrophy (DM) including DM1 and DM2. The compounds can disrupt the activity of Lin28 (e.g., Lin28A and/or Lin28B), RNA b...
|
|
WO/2024/075140A1 |
The present invention is in field of oral rehydration systems. More particularly, the present invention discloses rehydrating composition containing electrolytes along with postbiotic and zinc.
|
|
WO/2024/076177A1 |
The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and/or renal diseases in patients who have or are at risk of diabetes and/or rena...
|
|
WO/2024/076155A1 |
The present invention evaluated a method for producing a novel ENL/AF9 YEATS domain inhibitor, wherein the ENL/AF9 YEATS domain inhibition ability of a compound made through the production method was evaluated, and the novel compound was...
|
|
WO/2024/076530A1 |
This document provides methods and materials for treating a mammal (e.g., a human) having a disease or disorder condition associated with an elevated level of a plurality of senescence-associated secretory phenotype (SASP) polypeptides (...
|
|
WO/2024/074894A1 |
Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.
|
|
WO/2024/049829A3 |
A pharmaceutical composition comprising a compound a binding pocket adjacent the wedge domain of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTPμ) and that ...
|
|
WO/2024/077216A1 |
The disclosure is directed to compounds of Formula I (I). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2024/073669A1 |
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the ...
|
|
WO/2024/072437A1 |
The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (B...
|
|
WO/2024/071371A1 |
The present disclosure provides a heterocyclic compound. The disclosure relates to a compound in which a ligand of a specific E3 ligase is bound to an intracellular target protein ligand via a linker. More specifically, the disclosure ...
|
|
WO/2024/069009A1 |
The present disclosure relates to a method of treating hepatocellular carcinoma in a human subject comprising administering an anti-Claudin-1 antibody to a human subject, wherein the hepatocellular carcinoma is resistant to sorafenib and...
|
|
WO/2024/071464A1 |
The present invention relates to anticancer uses of a maleate metal salt. Particularly, the present invention relates to a pharmaceutical composition for preventing or treating cancer and an anticancer adjuvant pharmaceutical composition...
|
|
WO/2024/067819A1 |
A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
|
|
WO/2024/073559A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/073077A1 |
Methods for treating or preventing a disease or infection with MCP-1 involvement, or related symptoms, using an effective amount of tafenoquine are disclosed. Compositions for treating or preventing a disease or infection with MCP-1 invo...
|
|
WO/2024/066986A1 |
The present invention relates to a 2-aminopyrimidine compound, and a use and pharmaceutical composition thereof. The compound can inhibit CDK4 and CDK6 activity, in particular CDK4 activity with high selectivity, and treat or prevent hyp...
|
|
WO/2024/073475A1 |
Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain p...
|
|
WO/2024/073383A1 |
Disclosed herein are substituted compounds of formula (I), salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
|
|
WO/2024/067849A1 |
Provided are a liposome and a composition thereof. When the liposome and the composition thereof serve as a medicament carrier, by means of specific drug-loading conditions and processes, 1) a high drug-loading capacity (with the highest...
|
|
WO/2024/068672A1 |
The present invention relates to a composition for use in treating a condition of the lower gastrointestinal tract, e.g. ulcerative colitis, wherein the composition comprises: a) a carrier comprising: a1) water in an amount of more than ...
|
|
WO/2024/071077A1 |
The present invention addresses the problem of providing a food composition and an anti-obesity composition that reduce the area of abdominal fat at a low daily dosage. The present invention provides a food composition and an anti-obesit...
|
|
WO/2024/068693A1 |
This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro-particles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carri...
|
|
WO/2024/065892A1 |
Provided is use of a reagent for detecting an eosinophil, an eosinophil and a cytoplasm content thereof, and a lipid metabolite hydroxy docosahexaenoic acid, which belongs to the technical field of medical treatment and medicines. Provid...
|
|
WO/2024/069649A1 |
The present invention relates to storage-stable pharmaceutical compositions comprising a drug substance containing amine, and at least one excipient, wherein the nitrosamine impurities in the said compositions are within acceptable level...
|
|
WO/2024/067626A1 |
A composite, comprising: 3-hydroxybutyric acid; and one or more of potassium 3-hydroxybutyrate, or calcium 3-hydroxybutyrate, or magnesium 3-hydroxybutyrate. A composite, wherein the anion comprises 3-hydroxyvaleric acid, and the cation ...
|
|
WO/2024/071406A1 |
[Problem] To provide a water-in-oil emulsion composition and a water repellent agent, each of which exhibits excellent water repellency and excellent storage stability, while having less stickiness even if vaseline is contained therein. ...
|
|
WO/2024/068851A1 |
A novel process for preparation of crystalline forms and novel crystalline forms of 1-(8- bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-meth
ylazetidin-3-amine salts is provided along with pharmaceutical compositions comprising...
|
|
WO/2024/073129A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2024/072049A1 |
Provided are a: pharmaceutical combination, composition or kit for preventing, alleviating or treating dementia or cognitive impairment, containing donepezil or a pharmaceutically acceptable salt thereof, and rivastigmine or a pharmaceut...
|
|
WO/2024/072890A1 |
Methods and materials involved in reducing the level of a long noncoding RNA of fat mass and obesity-associated protein (FTO-IT1) in a cell are provided herein.
|
|
WO/2024/067802A1 |
The present application provides a compound represented by formula (I), a preparation method therefor, and use thereof. The compound provided in the present application can be used for inhibiting the activity of protein tyrosine phosphat...
|
|
WO/2024/067793A1 |
Provided in the present disclosure are compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions comprising same, and the use thereof. The compounds are particularly suitable for preparing dru...
|
|
WO/2024/068948A1 |
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
|
|
WO/2024/068740A1 |
The present invention relates to novel compounds of formula (I). These compounds are inhibitors of CDK9 and are useful in the treatment of a variety of diseases including hyperproliferative diseases, virally induced infectious diseases, ...
|
|
WO/2024/067604A1 |
The present invention provides a use of salvianolic acid A (SAA), as a raw material of a novel anti-aging drug, in cellular senescence therapy, tumor therapy, and life extension. According to the present invention, it is found that SAA c...
|
|
WO/2024/067709A1 |
Provided are a compound (I) or a pharmaceutically acceptable salt thereof, an ester thereof, an optical isomer thereof, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, an N-oxide thereof, an isotopical...
|
|
WO/2024/068242A1 |
A veterinary tablet immediate release formulation comprising: about 25% by weight of pregabalin; from 5% to 15% by weight of a meat flavour; from 58% to 69% by weight of microcrystalline cellulose; and from 1% to 2% by weight of a lubric...
|
|
WO/2024/071979A1 |
The present invention relates to an ophthalmic composition which comprises brimonidine or a salt thereof, SBE-β-CD or a salt thereof, and xanthan gum, is safe, and has excellent stability and therapeutic effects.
|
|
WO/2024/067731A1 |
Disclosed herein are an S-ketamine transdermal composition and a preparation method therefor and use thereof. The transdermal composition comprises S-ketamine or a pharmaceutically acceptable salt thereof, an acrylate pressure-sensitive ...
|
